Subtype
Pancreatobiliary Carcinoma
CI-CAN-00001365Explore in graph →
699 active trials8 approved drugs60 evidence items
- NCIt
- C166418
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001365Explore in graph →
Clinical trials
2,131 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (303)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05042128 | The ASCEND Study: Gemcitabine and Nab-Paclitaxel With LSTA1 (Certepetide) or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma(ASCEND) | unknown | Phase 2 | 158 | Australasian Gastro-Intestinal Trials GroupNETWORK | 2 | Oct 22, 2024 | clinicaltrials |
| NCT04913337 | Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | unknown | Phase 1 / Phase 2 | 179 | NGM Biopharmaceuticals, IncINDUSTRY |
| 3 |
| Oct 2, 2024 |
| clinicaltrials |
| NCT06006390 | CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 60 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06467565 | NALIRIFOX as Induction Therapy in LAPC | unknown | Phase 2 | 20 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 21, 2024 | clinicaltrials |
| NCT03337087 | Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer | unknown | Phase 1 / Phase 2 | 18 | Academic and Community Cancer Research UnitedOTHER | 1 | May 17, 2024 | clinicaltrials |
| NCT06375642 | A Single Arm, Single Centered Phase II Trial on the Combination of Adebrelimab, Surufatinib and Irinotecan Liposome-based HAIC in Advanced iCC | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT06335927 | HAIC Combined With Cadonilimab and Regorafenib as 2nd-line Treatment for ICC | unknown | Phase 2 | 45 | Fudan UniversityOTHER | 1 | Mar 28, 2024 | clinicaltrials |
| NCT05048524 | Peri-operative SLOG for Localized Pancreatic Cancer | unknown | Phase 2 | 64 | National Health Research Institutes, TaiwanOTHER | 1 | Mar 27, 2024 | clinicaltrials |
| NCT03924466 | Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients(VUBAR) | unknown | Phase 2 | 55 | Universitair Ziekenhuis BrusselOTHER | 1 | Feb 16, 2024 | clinicaltrials |
| NCT05955157 | Combined S-1 With DC+CIK As Maintenance Therapy For Advanced Pancreatic Ductal Adenocarcinoma | unknown | Phase 2 / Phase 3 | 52 | University of MalayaOTHER | 1 | Jan 10, 2024 | clinicaltrials |
| NCT06192784 | Combined DEB-TACE, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma(CCGLC-012) | unknown | Phase 2 | 36 | Tongji HospitalOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT06172634 | A Single-center Clinical Study to Evaluate the Safety and Efficacy of Autologous Bone Marrow-derived DCs(CellgramDC-WT1) and Immune Checkpoint Inhibitors in Patients With Metastatic Pancreatic Cancer Who Have Failed First-line or More Standard Chemotherapy(DICI_PC) | unknown | Phase 1 / Phase 2 | 10 | Soonchunhyang University HospitalOTHER | 0 | Dec 15, 2023 | clinicaltrials |
| NCT06168552 | Fluorescent Navigation Technology in Radical Resection of Pancreatic Cancer(CISPD-6) | unknown | Phase 1 / Phase 2 | 20 | Zhejiang UniversityOTHER | 0 | Dec 13, 2023 | clinicaltrials |
| NCT06134193 | Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer | unknown | Phase 2 | 41 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Nov 18, 2023 | clinicaltrials |
| NCT05781958 | Cadonilimab Combined With Gem/Cis as First Line Therapy in Patients With Advanced ICC | unknown | Phase 2 | 64 | Shen FengOTHER | 1 | Nov 2, 2023 | clinicaltrials |
| NCT06080854 | AG Combined With Immunotherapy and SBRT in Patients With Potentially Resectable Pancreatic Cancer | unknown | Phase 2 | 108 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Oct 12, 2023 | clinicaltrials |
| NCT05023109 | GP Chemotherapy in Combination With Anti-PD-1 and Anti-TIGIT in Unresectable Advanced BTC | unknown | Phase 2 | 45 | Shanghai Zhongshan HospitalOTHER | 1 | Aug 15, 2023 | clinicaltrials |
| NCT05913661 | Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 30 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT03820310 | Clinical Trial of Autologous Tcm Immunotherapy in ICC | unknown | Phase 2 | 20 | Newish Technology (Beijing) Co., Ltd.INDUSTRY | 1 | May 24, 2023 | clinicaltrials |
| NCT05822453 | Gemcitabine Plus S1 and Tislelizumab in the First Line Therapy of Advanced Biliary Tract Carcinoma | unknown | Phase 2 | 20 | Peking Union Medical College HospitalOTHER | 1 | Apr 20, 2023 | clinicaltrials |
| NCT04454905 | Camrelizumab in Combination With Apatinib in Advanced ICC: A Single-arm Phase II Study | unknown | Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | Apr 19, 2023 | clinicaltrials |
| NCT05400902 | HAIC Combined With Sintilimab and Bevacizumab for Unresectable Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 17 | Binkui LiOTHER | 1 | Apr 13, 2023 | clinicaltrials |
| NCT05805956 | IMM2902 in Patients With Advanced Solid Tumors Expressing HER2 | unknown | Phase 1 / Phase 2 | 105 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 1 | Apr 10, 2023 | clinicaltrials |
| NCT04565275 | A Study of ICP-192 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 45 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 2 | Mar 14, 2023 | clinicaltrials |
| NCT04984980 | Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab in Unresectable Biliary Tract Cancer | unknown | Phase 2 | 37 | Fudan UniversityOTHER | 1 | Jan 26, 2023 | clinicaltrials |
| NCT05672537 | Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk | unknown | Phase 2 | 70 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 5, 2023 | clinicaltrials |
| NCT05641233 | Preoperative Radiotherapy in Patients at High Risk of Postoperative Pancreatic Fistula After Pancreatoduodenectomy(FIBROPANC-1) | unknown | Phase 1 / Phase 2 | 33 | Erasmus Medical CenterOTHER | 1 | Dec 7, 2022 | clinicaltrials |
| NCT05634564 | Concurrent Chemoradiotherapy Combined With Immunotherapy in Patients With Potentially Resectable Pancreatic Cancer | unknown | Phase 2 | 62 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Dec 5, 2022 | clinicaltrials |
| NCT05627427 | Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard Chemotherapy | unknown | Phase 2 | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 25, 2022 | clinicaltrials |
| NCT05350943 | HAIC Combined With Toripalimab and Donafenib for Advanced BTC | unknown | Phase 2 | 70 | Lu Wang, MD, PhDOTHER | 1 | Oct 18, 2022 | clinicaltrials |
| NCT05535647 | Second Line Therapy for Advanced Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT04782804 | Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative Recurrence | unknown | Phase 1 / Phase 2 | 30 | Fudan UniversityOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT05181605 | Survival Analysis After Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer and Risk Factors | unknown | Phase 2 / Phase 3 | 116 | Instituto de investigación e innovación biomédica de CádizOTHER | 1 | Aug 9, 2022 | clinicaltrials |
| NCT05290116 | HAIC Combined With Tislelizumab and Apatinib for Unresectable Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 17 | Yunfei YuanOTHER | 1 | Aug 5, 2022 | clinicaltrials |
| NCT02839343 | Combination Chemotherapy With or Without Hypofractionated Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer | unknown | Phase 2 | 126 | Alliance for Clinical Trials in OncologyOTHER | 2 | May 24, 2022 | clinicaltrials |
| NCT03086993 | Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma | unknown | Phase 2 / Phase 3 | 295 | Delcath Systems Inc.INDUSTRY | 1 | Mar 24, 2022 | clinicaltrials |
| NCT04835402 | Electroporation Potentiated Immunotherapy in Cancer(EPIC-1) | unknown | Phase 2 | 8 | Ole Thorlacius-Ussing, MD, DMSc, Professor of SurgeryOTHER | 1 | Mar 9, 2022 | clinicaltrials |
| NCT05257122 | A Phase II Clinical Trial of Fruquintinib as Third Line Treatment in Advanced Pancreatic Cancer | unknown | Phase 2 | 32 | Fudan UniversityOTHER | 1 | Feb 25, 2022 | clinicaltrials |
| NCT05251662 | Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 90 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 23, 2022 | clinicaltrials |
| NCT03221400 | PEN-866 in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 340 | Tarveda TherapeuticsINDUSTRY | 1 | Feb 17, 2022 | clinicaltrials |
| NCT05207735 | PD-1 Inhibitor Sintilimab Combined With Capecitabine for Adjuvant Treatment After Radical Resection of Cholangiocarcinoma.(SCRCA) | unknown | Phase 2 | 73 | Henan Cancer HospitalOTHER_GOV | 0 | Jan 26, 2022 | clinicaltrials |
| NCT04652206 | Clinical Trial to Investigate Safety, Tolerability and MTD for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients.(PANTAX-Ib) | unknown | Phase 1 / Phase 2 | 18 | Scandion Oncology A/SINDUSTRY | 2 | Dec 29, 2021 | clinicaltrials |
| NCT05143151 | CD276-targeted Chimeric Antigen Receptor T Cells in Treatment With Advanced Pancreatic Cancer(CAR-T) | unknown | Phase 1 / Phase 2 | 10 | Shenzhen University General HospitalOTHER | 1 | Dec 3, 2021 | clinicaltrials |
| NCT05066802 | A Phase 2 Trial of Neoadjuvant Modified FOLFIRINOX Chemotherapy for Resectable Pancreatic Adenocarcinoma | unknown | Phase 2 | 27 | Yonsei UniversityOTHER | 1 | Oct 4, 2021 | clinicaltrials |
| NCT03603834 | Neoadjuvant mFOLFOXIRI for Potentially Resectable Cholangiocarcinoma | unknown | Phase 2 | 25 | Khon Kaen UniversityOTHER | 1 | Sep 1, 2021 | clinicaltrials |
| NCT04718701 | Anlotinib, Toripalimab and Nab-paclitaxel in Locally Advanced/Metastatic Pancreatic Cancer(ATNPA) | unknown | Phase 2 | 53 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 16, 2021 | clinicaltrials |
| NCT04979663 | GEMOX Combined With Donafenib and Tislelizumab in Biliary Tract Cancer | unknown | Phase 1 / Phase 2 | 10 | Fudan UniversityOTHER | 1 | Aug 9, 2021 | clinicaltrials |
Data updated 22 days agoSource updated Oct 22, 2024source: clinicaltrials